Harvard Bioscience, Inc. (HBIO) Stock Forecast
HBIO analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.50 / 5 from 2 analysts
- Price target
- $7.50 average of analyst targets
- Upside to target
- −7.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.17
- 52-week range
- $3.98 – $8.56
HBIO analyst ratings
2 analystsNumber of analysts at each rating.
HBIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HBIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.31 | −$0.03 | $0.00 | 0.0% | 2 |
| Current fiscal year (2026) | −$0.38 | −$0.62 | −$0.14 | −$0.20 | −90.0% | 2 |
| Next fiscal year (2027) | $0.65 | $0.37 | $0.92 | −$0.38 | +269.7% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HBIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $21.8M | $21.6M | $22.0M | +5.9% | 2 |
| Current fiscal year (2026) | $89.8M | $89.6M | $90.0M | +3.8% | 2 |
| Next fiscal year (2027) | $94.5M | $93.6M | $95.5M | +5.3% | 2 |
HBIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HBIO revenue: reported and forecast
HBIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.27 | −$0.27 | −$0.27 | −$0.27 | −$0.17 | −37.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.70 | −$0.70 | −$0.70 | −$0.70 | −$0.38 | −45.7% | 0 up · 0 down |
| Next fiscal year (2027) | $0.44 | $0.44 | $0.44 | $0.44 | $0.65 | +46.6% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HBIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HBIO beat in 3 of 12.
What analysts expect from HBIO
2 analysts cover Harvard Bioscience; their consensus rating is buy (3.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.50, 7.3% below the latest close of $8.09. Analysts expect earnings of −$0.38 per share for 2026, −90.0% from a year earlier. For 2027 the average estimate is $0.65 per share on revenue of $94.5 million. Harvard Bioscience beat the EPS estimate in 3 of the last 12 quarters.
Related: HBIO income statement, HBIO key metrics, HBIO chart. See the HBIO stock overview for the latest quote and news.
HBIO forecast FAQ
What is Harvard Bioscience's price target?
The average analyst price target for Harvard Bioscience is $7.50, 7.3% below the latest close of $8.09.
Is Harvard Bioscience a buy, hold or sell?
Of 2 analysts covering Harvard Bioscience, 0 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Harvard Bioscience's EPS forecast?
Analysts forecast −$0.38 per share for 2026 (range −$0.62 to −$0.14); for 2027 the estimate is $0.65.
What is Harvard Bioscience's revenue forecast?
The average revenue estimate for 2026 is $89.8 million, growth of 3.8%; for 2027 it is $94.5 million.
When does Harvard Bioscience report earnings?
Harvard Bioscience is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.17.
Does Harvard Bioscience usually beat earnings estimates?
Harvard Bioscience reported EPS at or above the analyst estimate in 3 of the last 12 quarters.